 "Aurobindo Pharma")
Aurobindo Pharma Limited is looking at Eastern Europe as a priority market for inorganic growth as it seeks to further expand its European operations, which came as a strong insurance in the face of headwinds from the US market in the form of steep price erosion.
"We always actively pursue M&A opportunities for the purpose of market penetration and for new product platforms. When it comes to geographical preference Eastern Europe is more attractive in terms of priority," N Govinda Rajan said in response to a question during the analysts call yesterday.
The company's acquisition-led strategy has paid off in
